Accelerating translational research through Cardiff University’s Clinical Innovation pipeline
Lead Research Organisation:
CARDIFF UNIVERSITY
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept (CIC) scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions to flexibly support a portfolio of early stage translational research projects. CIC is designed to accelerate the transition from discovery research to viable translational projects by supporting preliminary studies to establish proof-of-concept so that the approach will then become competitive for more substantial translational funding.
Organisations
- CARDIFF UNIVERSITY (Lead Research Organisation)
- Cellesce Ltd (Collaboration)
- PTC Therapeutics (Collaboration)
- University College London (Collaboration)
- BIOINDUSTRY ASSOCIATION (Collaboration)
- UNIVERSITY OF MANCHESTER (Collaboration)
- University Hospitals Coventry and Warwickshire NHS Trust (Collaboration)
People |
ORCID iD |
| Ian Weeks (Principal Investigator) |
Publications
Collaborative Group On Duodenal Polyposis In MAP
(2021)
Duodenal Adenomas and Cancer in MUTYH-associated Polyposis: An International Cohort Study.
in Gastroenterology
Elvers KT
(2022)
Structures of the Human SPAK and OSR1 Conserved C-Terminal (CCT) Domains.
in Chembiochem : a European journal of chemical biology
Kodosaki E
(2024)
Combination protein biomarkers predict multiple sclerosis diagnosis and outcomes.
in Journal of neuroinflammation
| Description | Development of an oral drug delivery platform |
| Amount | £20,000 (GBP) |
| Organisation | Higher Education Innovation Funding (HEIF) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2020 |
| End | 08/2020 |
| Description | Non-invasive prediction of disability in progressive MS2 |
| Amount | £48,755 (GBP) |
| Organisation | Multiple Sclerosis Society |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2024 |
| End | 09/2025 |
| Description | BIA Pulse 2021 |
| Organisation | BioIndustry Association |
| Country | United Kingdom |
| Sector | Charity/Non Profit |
| PI Contribution | Dr. Foley has been invited to participate in BIA Pulse 2021 in March, a leadership and entrepreneurship training programme developed by the BIA and the Francis Crick Institute. |
| Collaborator Contribution | The programme is for aspiring entrepreneurs and new CEOs looking for advanced practical advice, support and feedback from leading entrepreneurs, renowned professionals and CEOs. |
| Impact | ongoing |
| Start Year | 2021 |
| Description | Collaboration Agreement |
| Organisation | Cellesce Ltd |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Collaboration agreement between Cellesce Ltd and Cardiff University for scale up and commercial use of organoids. |
| Collaborator Contribution | Collaboration agreement between Cellesce Ltd and Cardiff University for scale up and commercial use of organoids. Cellesce are continuing to provide their knowledge and expertise in organoid culture. |
| Impact | Permanent academic lectureship post for original PI, Dr Laura Thomas at Swansea university. |
| Start Year | 2020 |
| Description | Collaboration with Tarunya Arun, Coventry |
| Organisation | University Hospitals Coventry and Warwickshire NHS Trust |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | To study similar panel of biomarkers in NeuroSarcoid |
| Collaborator Contribution | Cardiff University was identified as a research collaborator in a grant awarded by Ferblanc to Tarunya Arun , "Diagnostic and predictive biomarkers in Neurosarcoidosis and Multiple Sclerosis: A prospective study" |
| Impact | NA |
| Start Year | 2022 |
| Description | Commitment for future collaboration |
| Organisation | PTC Therapeutics |
| Country | United States |
| Sector | Private |
| PI Contribution | This study used a novel model of disease (the first FAP associated duodenal tumours). It also focused on a novel approach to treatment, a genetically targeted therapy for a specific disease mechanism (nonsense mediated FAP). |
| Collaborator Contribution | Written support from PTC Therapeutics (developer and marketing authorisation holder for ataluren) for studies trialling ataluren in FAP. |
| Impact | Written support from PTC Therapeutics (developer and marketing authorisation holder for ataluren) for studies trialling ataluren in FAP. |
| Start Year | 2020 |
| Description | UCL collab to validate the biomarker panel in 2 new cohorts. - Diagnostic and predictive biomarkers in Multiple Sclerosis plasma: a comprehensive Screening approach. |
| Organisation | University College London |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | expertise and intellectual input |
| Collaborator Contribution | expertise and intellectual input |
| Impact | research grant (also recorded under funding) - MS Society Catalyst award to validate biomarker work in 2 new cohorts of people with MS (one UCL and one Cardiff). "Non-invasive prediction of disability in progressive MS2" £48755.73. 01/10/2024 - 20/09/2025. Multiple Sclerosis Society. Research Grant/Catalyst Award. |
| Start Year | 2024 |
| Description | University of Manchester Discovery and Development of SPAK and OSR1 Kinase Inhibitors as Novel Treatments for Ischemic Strokes |
| Organisation | University of Manchester |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Discovery and Development of SPAK and OSR1 Kinase Inhibitors as Novel Treatments for Ischemic Strokes |
| Collaborator Contribution | Discovery and Development of SPAK and OSR1 Kinase Inhibitors as Novel Treatments for Ischemic Strokes |
| Impact | N/A |
| Start Year | 2022 |